# Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease

> **NCT02425111** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 101 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Vedolizumab

## Key facts

- **NCT ID:** NCT02425111
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-30
- **Primary completion:** 2017-06-02
- **Final completion:** 2018-02-21
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2018-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02425111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02425111, "Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02425111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*